| Patient | Albert Einstein |
|---|---|
| Date of birth | 1956-03-14 |
| Identifiers | MRN HR-ET012-SYN; SSN (made up) 000-12-6650 |
| Document date | 2026-07-14 |
| Author | Clementine Ward, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Three-month review of blood pressure, cholesterol, and smoking cessation. [S]
Mr. Einstein returns about four months after his first visit. He has had no tobacco since his quit date and has had no cravings strong enough to need more than one or two lozenges a day for the past month; he still holds an empty pipe at his desk. His home blood pressure readings average 124/74 on amlodipine 5 mg and losartan 100 mg. He takes atorvastatin 40 mg and aspirin 81 mg without muscle aches, bruising, or bleeding. The back strain six weeks ago settled within ten days, and he has had no abdominal, back, or flank pain since. The lipid panel was not drawn in the first twelve weeks on atorvastatin, because no standing order was placed after the four-week visit; it was drawn today. [S]
| Element | Detail |
|---|---|
| Tobacco | Tobacco-free since the quit date; one or two lozenges a day |
| Blood pressure | Home average 124/74 |
| Medicines | Amlodipine 5 mg, losartan 100 mg, atorvastatin 40 mg, aspirin 81 mg; no side effects |
| Interval illness | Low back strain six weeks ago, resolved |
| System | Result | Finding |
|---|---|---|
| Cardiovascular | Negative | No chest pain, fainting, or leg pain on walking |
| Gastrointestinal | Negative | No abdominal pain or black stools |
| Musculoskeletal | Negative | Back pain resolved; no muscle aches |
| Hematologic | Negative | No easy bruising or bleeding |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Amlodipine 5 mg oral tablet, one tablet daily | One tablet by mouth each morning | Oral route | 2025-05-20 | active | S |
| Losartan 50 mg oral tablet, one tablet daily | One tablet by mouth each morning | Oral route | 2026-03-24 to 2026-04-21 | completed | S |
| Losartan 100 mg oral tablet, one tablet daily | One tablet by mouth each morning | Oral route | 2026-04-21 | active | S |
| Atorvastatin 40 mg oral tablet, one tablet daily | One tablet by mouth each evening | Oral route | 2026-03-24 | active | S |
| Aspirin 81 mg delayed-release oral tablet, one tablet daily | One tablet by mouth daily with food | Oral route | 2026-04-21 | active | S |
| Nicotine 14 mg/24 hour transdermal patch, one patch daily | Apply one new patch each morning | Topical route | 2026-03-24 to 2026-07-14 | completed | S |
| Nicotine 7 mg/24 hour transdermal patch, one patch daily | Apply one new patch each morning | Topical route | 2026-07-14 to 2026-09-22 | completed | S |
| Nicotine 2 mg lozenge as needed for cravings | Dissolve one lozenge in the mouth for a craving, no more often than every 2 hours and no more than 20 a day | Oral route | 2026-03-24 to 2026-09-22 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-07-14 | Body height | 172 | cm | S |
| 2026-07-14 | Body weight | 79.4 | kg | S |
| 2026-07-14 | Body mass index (BMI) [Ratio] | 26.8 | kg/m2 | S |
| 2026-07-14 | Systolic blood pressure | 126 | mm[Hg] | S |
| 2026-07-14 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-07-14 | Heart rate | 68 | /min | S |
| 2026-07-14 | Respiratory rate | 14 | /min | S |
| 2026-07-14 | Body temperature | 36.6 | Cel | S |
| 2026-07-14 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-07-14 | Sodium [Moles/volume] in Serum or Plasma | 139 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-07-14 | Potassium [Moles/volume] in Serum or Plasma | 4.7 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-07-14 | Creatinine [Mass/volume] in Serum or Plasma | 1.1 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-07-14 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 70 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-07-14 | Cholesterol [Mass/volume] in Serum or Plasma | 132 | mg/dL | <=200 mg/dL | Normal | S |
| 2026-07-14 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 46 | mg/dL | >=40 mg/dL | Normal | S |
| 2026-07-14 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 62 | mg/dL | <=129 mg/dL | Normal | S |
| 2026-07-14 | Triglyceride [Mass/volume] in Serum or Plasma | 120 | mg/dL | <=149 mg/dL | Normal | S |
Vital signs recorded on 2026-07-14; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; weight 79.4 kg |
| Cardiovascular | Regular rhythm at 68 per minute; blood pressure 126/76 mmHg |
| Abdomen | Pulsatile, non-tender mass above the umbilicus |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Infrarenal abdominal aortic aneurysm, 5.0 cm by duplex ultrasound, found and wrapped at a prior exploratory laparotomy; under surveillance below the repair threshold | active | confirmed | I71.43 | S — Synthetic modern coding anchored to the documented aneurysm found and wrapped at his exploratory laparotomy; the diameter and all surveillance are synthetic. |
| Essential hypertension | active | confirmed | I10 | S — Synthetic risk factor in the modern frame; no historical blood pressure is documented in the cited sources. |
| Nicotine dependence, pipe tobacco | active | confirmed | F17.290 | S — Synthetic modern coding anchored to his documented pipe smoking. |
| Atherosclerosis of the abdominal aorta, with calcified atheroma on CT angiography | active | confirmed | I70.0 | S — Synthetic finding on the baseline CT angiography. |
| Acute low back strain after lifting, with aneurysm symptoms excluded; resolved | resolved | confirmed | S39.012A | S — Synthetic intercurrent illness at an unscheduled visit, chosen to teach how new back pain is assessed in a patient with a known aneurysm. It does not echo a documented illness. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Imaging | Aneurysm diameter by duplex ultrasound (CT if views are poor) | Every 6 months at 5.0 to 5.4 cm in men; yearly at 4.0 to 4.9 cm | Up to date | 5.0 cm by duplex ultrasound at the sick visit six weeks ago, unchanged; next scan at six months |
| Imaging | CT angiography for baseline anatomy and repair planning | Once at baseline; again when repair is considered | Up to date | Baseline done; repeat only if repair is considered |
| Examination | Femoral and popliteal arteries for a coexisting aneurysm | Once at diagnosis | Up to date | Normal on examination; popliteal duplex planned with the six-month scan |
| Examination | Aneurysm symptoms and tenderness, with the emergency plan reviewed | Every visit | Completed today | No pain or tenderness since the back strain resolved; emergency plan reviewed |
| Referral | Vascular surgery review and shared decision on elective repair | At baseline, then at a threshold change or yearly | Up to date | Shared decision recorded at the four-week visit; review at the six-month scan |
| Examination | Blood pressure, target below 130/80 | Every visit | Completed today | 126/76 mmHg; at target |
| Self-management | Home blood pressure readings | Before each visit while treatment is being adjusted | Completed today | Home average 124/74 |
| Laboratory | Metabolic panel (sodium, potassium, creatinine, eGFR) | 2 to 4 weeks after starting or changing losartan; then every 6 months | Completed today | After the losartan increase: sodium 139, potassium 4.7, creatinine 1.10 mg/dL, eGFR 70; next in six months |
| Laboratory | Lipid panel | 4 to 12 weeks after starting a statin; then yearly | Deferred | Not drawn within the 4 to 12 week window after atorvastatin was started, a deviation from the protocol: no standing order was placed at the four-week visit and no visit fell before twelve weeks. Judging by today's result, no harm resulted. Corrective action: standing laboratory orders are placed at each visit for tests due before the next one |
| Laboratory | Lipid panel | 4 to 12 weeks after starting a statin; then yearly | Completed today | Drawn today at sixteen weeks: total cholesterol 132, HDL 46, LDL 62, triglycerides 120 mg/dL; LDL down 56 percent and below 70 |
| Laboratory | ALT | Once before a statin; then only with symptoms | Not indicated | No muscle or liver symptoms; routine repeat not recommended |
| Laboratory | HbA1c | Yearly | Up to date | 5.6 percent in March; repeat yearly |
| Laboratory | Urine albumin-to-creatinine ratio | Yearly | Up to date | 14 mg/g in March; repeat yearly |
| Medication safety | Statin adherence and muscle symptoms | Every visit | Completed today | Adherent; no muscle aches |
| Medication safety | Low-dose aspirin: indication and bleeding | Every visit while taking it | Completed today | No bruising, black stools, or bleeding |
| Medication safety | Medication review: avoid fluoroquinolones and anti-inflammatory pain medicines | Every visit | Completed today | Acetaminophen only for the back strain; no anti-inflammatory or fluoroquinolone use |
| Self-management | Tobacco use and cessation support (5 A's, nicotine replacement) | Every visit | Completed today | Tobacco-free about fifteen weeks; patch stepped down to 7 mg |
| Examination | 12-lead ECG | Baseline with hypertension; repeat as indicated | Up to date | Normal at the four-week visit |
| Examination | Ankle-brachial index | Every 2 to 3 years at 65 or older or with a smoking history | Due | With the six-month duplex scan |
| Examination | Eye examination for hypertensive retinopathy | Yearly | Due | To be arranged at the wellness visit |
| Examination | Weight and BMI | Every visit | Completed today | 79.4 kg; BMI 26.8 |
Goal progress:
Guideline basis: The Society for Vascular Surgery practice guidelines on the care of patients with an abdominal aortic aneurysm (2018); 2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease (2022); CMID: Clinical Monitoring Intelligence Database, Hypertension and Hyperlipidemia monographs (2026); Tobacco Smoking Cessation in Adults, Including Pregnant Persons: Interventions (2021)
Follow-up: Annual wellness visit in about six weeks. Six-month surveillance visit with duplex ultrasound, popliteal duplex, and ankle-brachial index. Next scheduled visit 2026-08-25: subsequent annual wellness visit. [S]